293 related articles for article (PubMed ID: 32708452)
1. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
[TBL] [Abstract][Full Text] [Related]
2. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
[TBL] [Abstract][Full Text] [Related]
4. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
5. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
6. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
8. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
[TBL] [Abstract][Full Text] [Related]
9. MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells.
Hu N; Chen L; Wang C; Zhao H
Biomed Pharmacother; 2019 Apr; 112():108720. PubMed ID: 30970520
[TBL] [Abstract][Full Text] [Related]
10. GLI3 knockdown decreases stemness, cell proliferation and invasion in oral squamous cell carcinoma.
Rodrigues MFSD; Miguita L; De Andrade NP; Heguedusch D; Rodini CO; Moyses RA; Toporcov TN; Gama RR; Tajara EE; Nunes FD
Int J Oncol; 2018 Dec; 53(6):2458-2472. PubMed ID: 30272273
[TBL] [Abstract][Full Text] [Related]
11. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
12. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells.
Kobune M; Takimoto R; Murase K; Iyama S; Sato T; Kikuchi S; Kawano Y; Miyanishi K; Sato Y; Niitsu Y; Kato J
Cancer Sci; 2009 May; 100(5):948-55. PubMed ID: 19245435
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
15. Gli3 mediates cell survival and sensitivity to cyclopamine in pancreatic cancer.
Steg A; Amm HM; Novak Z; Frost AR; Johnson MR
Cancer Biol Ther; 2010 Nov; 10(9):893-902. PubMed ID: 20814245
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
[TBL] [Abstract][Full Text] [Related]
17. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.
Karathedath S; Rajamani BM; Musheer Aalam SM; Abraham A; Varatharajan S; Krishnamurthy P; Mathews V; Velayudhan SR; Balasubramanian P
PLoS One; 2017; 12(5):e0177227. PubMed ID: 28505160
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
19. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
[TBL] [Abstract][Full Text] [Related]
20. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]